Skip to main content
AROA BIOSURGERY LIMITED logo

AROA BIOSURGERY LIMITED — Investor Relations & Filings

Ticker · ARX ISIN · NZARXE0001S1 ASX Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2020-11-25 Interim / Quarterly Rep…
Country AU Australia
Listing ASX ARX

About AROA BIOSURGERY LIMITED

https://aroa.com/

Aroa Biosurgery Limited specializes in the development and commercialization of regenerative medical devices for wound healing and soft tissue reconstruction. The company’s core technology is the AROA ECM platform, a proprietary extracellular matrix derived from ovine forestomach tissue. This scaffold-based technology is engineered to facilitate host cell infiltration and promote new blood vessel formation, supporting the body's natural healing process. The product portfolio includes Endoform for chronic and acute wound management, Myriad for complex surgical applications, and Symphony for skin substitute procedures. Additionally, the company manufactures the Ovitex and Ovitex PRS reinforced tissue matrices for hernia repair and breast reconstruction. These solutions target clinical needs in advanced wound care and surgical specialties by providing biological scaffolds that integrate into host tissue.

Recent filings

Filing Released Lang Actions
Aroa Half Year Results 4 pages 181.3KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 26 November 2020, titled 'AROA BIOSURGERY HALF YEARLY REPORT H1 FY21'. It contains detailed financial data for the half-year ended 30 September 2020, including product revenues, gross margin, operating expenses, and management commentary on business operations and outlook. The document includes unaudited financial figures and discusses performance trends, product pipeline, and strategic initiatives. The length is approximately 14,791 characters, indicating a substantive report rather than a brief announcement. The content and structure align with a comprehensive interim or quarterly financial report rather than a simple earnings release or announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR), which includes comprehensive financial data and analysis for a period shorter than a full fiscal year.
2020-11-25 English
Appendix 4D and Half Year Report 28 pages 1.1MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALF-YEAR FINANCIAL REPORT TO 30 SEPTEMBER 2020' and references Appendix 4D under ASX Listing Rule 4.2A, which is a standard half-year reporting requirement for Australian Securities Exchange listed companies. It contains detailed financial data for the half-year period ending 30 September 2020, including revenue, loss, net tangible assets, and operational commentary. It also includes a Directors' Report and consolidated financial statements, as well as an Independent Auditor's Review Report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and structure align with an Interim / Quarterly Report, providing comprehensive financial statements and analysis for a period shorter than a full fiscal year. Therefore, the appropriate classification is 'Interim / Quarterly Report' (IR).
2020-11-25 English
Aroa Half Year Results Webinar 1 page 122.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 26 November 2020, inviting investors to a webinar to discuss the company's Half Year Results. It does not contain the actual half-year financial report or substantive financial data, but rather is an announcement of an event to discuss the results. The document length is short (2111 characters), and it primarily serves as a notification for a webinar related to the interim results. According to the 'Menu vs Meal' rule, this is not the interim report itself but an announcement related to it. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2020-11-25 English
Myriad shown to be effective in surgical treatment of HS 2 pages 164.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement/media release dated 12 November 2020 from Aroa Biosurgery Limited. It discusses clinical study results and peer-reviewed publication validation for their product Myriad™, focusing on its effectiveness in surgical treatment of Hidradenitis Suppurativa. The content is promotional and informative about product validation, clinical study outcomes, regulatory clearances, and market potential. There are no financial statements, earnings data, management discussion of financial results, or regulatory filings related to financial performance. The document is not a report itself but an announcement of clinical and product validation results. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2020-11-11 English
Aroa to present at NWR Virtual Investor Conference 1
Investor Presentation Classification · 90% confidence The document is an announcement dated 4 November 2020 from Aroa Biosurgery Limited about the CEO and CFO delivering an investor presentation at the NWR Virtual Investor Conference on 5 November 2020. It includes details about the presentation time, registration link, and contact information. There is no financial data, report, or detailed analysis included. The document is clearly an announcement of an upcoming investor presentation rather than the presentation itself or a financial report. Therefore, the appropriate classification is Investor Presentation (IP). However, since the document is announcing the presentation rather than containing the presentation content, it fits best as an Investor Presentation announcement. Given the definitions, the closest match is Investor Presentation (IP) as it focuses on financials, strategy, and market position, which is the purpose of the event being announced.
2020-11-03 English
September Quarterly Report and Appendix 4C 9 pages 287.4KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 27 October 2020, titled "Aroa Biosurgery Quarterly Activities Report & 4C September 2020." It provides detailed financial commentary for the quarter ended 30 September 2020, including unaudited product revenues, cash flow from operations, and cash on hand. It also includes an Appendix 4C, which is a quarterly cash flow report required under ASX Listing Rule 4.7B. The document discusses operational highlights, regulatory approvals, market expansion, and the impact of COVID-19. The presence of the Appendix 4C quarterly cash flow report and the detailed financial data for a quarter strongly indicate this is an Interim / Quarterly Report. It is not a full Annual Report (10-K), nor is it merely an announcement of a report (RPA). It contains substantive financial data and analysis for a period shorter than a full fiscal year, meeting the criteria for an Interim / Quarterly Report (IR).
2020-10-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.